Bey Douglas LLC Increases Position in Stryker Corporation $SYK

Key Points

• Bey Douglas LLC has increased its holdings in Stryker Corporation by 39.4%, now owning 19,504 shares valued at approximately $7.7 million.
• Stryker achieved a quarterly earnings per share of $3.13, surpassing analysts' expectations, with a revenue of $6.02 billion.
• The company recently declared a quarterly dividend of $0.84 per share, with a dividend yield of 0.9% and a payout ratio of 44.50%.

Bey Douglas LLC increased its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 39.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,504 shares of the medical technology company's stock after purchasing an additional 5,513 shares during the quarter. Stryker makes up approximately 4.6% of Bey Douglas LLC's holdings, making the stock its 7th largest holding. Bey Douglas LLC's holdings in Stryker were worth $7,716,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Sachetta LLC grew its stake in shares of Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock worth $29,000 after purchasing an additional 27 shares during the last quarter. Goodman Advisory Group LLC bought a new stake in shares of Stryker in the first quarter worth about $32,000. Ridgewood Investments LLC grew its stake in shares of Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock worth $36,000 after purchasing an additional 30 shares during the last quarter. Ransom Advisory Ltd bought a new stake in shares of Stryker in the first quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Stryker in the first quarter worth about $40,000. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

Shares of SYK opened at $364.77 on Friday. The company has a market capitalization of $139.46 billion, a P/E ratio of 48.31, a price-to-earnings-growth ratio of 2.67 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $380.25 and a 200 day moving average of $378.75. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm's quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker's dividend payout ratio (DPR) is 44.50%.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

SYK has been the subject of several research analyst reports. Rothschild Redb upgraded shares of Stryker to a "hold" rating in a report on Thursday, September 18th. Evercore ISI lowered their price objective on shares of Stryker from $418.00 to $410.00 and set an "outperform" rating for the company in a report on Tuesday. Wall Street Zen lowered shares of Stryker from a "buy" rating to a "hold" rating in a report on Friday, September 26th. Weiss Ratings restated a "buy (b-)" rating on shares of Stryker in a report on Wednesday. Finally, Wells Fargo & Company raised their price objective on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus target price of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.